Compare Pelat Timah Nusantara Tbk. (NIKL) vs Brigit Biofarmaka Teknologi Tbk. (OBAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pelat Timah Nusantara Tbk. vs Brigit Biofarmaka Teknologi Tbk. — how do they compare? Pelat Timah Nusantara Tbk. trades at Rp197 (market cap 492.05B, 3.66M 24h volume), while Brigit Biofarmaka Teknologi Tbk. trades at Rp254 (market cap 172.82B, 592.2K 24h volume). The key difference: Pelat Timah Nusantara Tbk. is far larger — about 2.8× Brigit Biofarmaka Teknologi Tbk.'s market cap, and Pelat Timah Nusantara Tbk. is more actively traded (3.66M versus 592.2K). Which is the better fit depends on your goals.
| NIKL | OBAT | |
|---|---|---|
Market Cap | 492.05B | 172.82B |
Volume | 3.66M | 592.2K |
Lot | 36.64K | 5.92K |
Turnover | 716.64M | 147.05M |
Average Price | 195.61 | 248.31 |
Value | 716.64M | 147.05M |
Indicative Equilibrium Price | 197 | 254 |
Indicative Equilibrium Volume | 149 | 10 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pelat Timah Nusantara Tbk.
PT Pelat Timah Nusantara Tbk (PT Latinusa) was the first company in Indonesia that produces high-quality tinplate with international standards. PT Latinusa was founded on August 19, 1982 under the Company Act No.45, drawn up before Imas Fatimah, SH, and the current majority shareholder is the Japanese consortium consisting of Nippon Steel Corporation, Mitsui Co.. Ltd.., Nippon Steel Trading Co.., And Metal One. Nippon Steel Corporation is also the provider of our main raw material, Tin Mill Black Plate (TMBP), so the availability of raw materials is always guaranteed.
Read more on NIKL →About Brigit Biofarmaka Teknologi Tbk.
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →
